Log In
BCIQ
Print this Print this
 

flutiform, flutiformo, Fluticasone propionate/formoterol (KRP-108)

  Manage Alerts
Collapse Summary General Information
Company Vectura Group plc
DescriptionFixed-dose combination of formoterol, a long-acting adrenergic receptor beta 2 agonist (LABA), and fluticasone propionate, an inhaled corticosteroid, delivered via a hydrofluoroalkane metered-dose inhaler (HFA-MDI)
Molecular Target Adrenergic receptor beta 2 (ADRB2) ; Glucocorticoid receptor (GCCR)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalitySmall molecule: Combination

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$634.2M

$100.6M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/10/2016

$634.2M

$100.6M

0

08/01/2011

Undisclosed

0

Undisclosed

Get a free BioCentury trial today